COVID-19 vaccine maker Vaccitech targets $613 million valuation in US IPO



Biotech startup Vaccitech, which co-invented the COVID-19 vaccine developed by AstraZeneca Plc and Oxford University, said on Monday it was aiming for a valuation of up to $613 million in its US initial public offering.



Source link

Leave a Reply

Pin System